Tyra Biosciences Q2 2026: $353.9M Cash, Pipeline Progress, and Key Leadership Hire
TYRA has more than doubled off its 52-week low of $9.96.
Summary
Tyra Biosciences posted a $45.6M net loss for Q2 2026 while holding $353.9M in cash. The company amended its ATM agreement to sell up to an additional $250M in shares and provided updates on upcoming clinical data readouts for its lead candidate dabogratinib.
Key Events · Earnings and Guidance · TYRA
-
Q2 2026 Financial Results
A net loss of $45.6 million ($0.69/share) was driven by R&D spend of $39.2 million and G&A of $9.8 million. Cash, equivalents, and marketable securities totaled $353.9 million as of June 30, 2026, which is expected to fund operations into the second half of 2028.
-
Amended ATM Sales Agreement
An amended sales agreement with TD Securities allows the company to sell up to an additional $250 million of common stock from time to time in at-the-market offerings, adding to the existing ATM program that previously raised $147.9 million.
-
Upcoming Clinical Milestones
Initial Phase 2 SURF302 data for dabogratinib in IR NMIBC is expected in September 2026, with over 40 patients enrolled. Meanwhile, initial BEACH301 safety sentinel cohort data in achondroplasia is now expected by the end of Q1 2027.
-
Executive Appointment
Jonathan Day has been appointed as EVP, Clinical Development to lead the skeletal dysplasia strategy. Dr. Day previously led vosoritide development at BioMarin.
Analysis · TYRA · Life Sciences
With a net loss of $45.6 million and $353.9 million in cash, Tyra Biosciences extended its runway into the second half of 2028. An amended ATM sales agreement for up to an additional $250 million could dilute existing shareholders but bolsters financial flexibility. Key clinical milestones are approaching: initial Phase 2 SURF302 data in September 2026 and BEACH301 safety sentinel cohort data by end of Q1 2027. The appointment of Jonathan Day, a veteran in skeletal dysplasia drug development, strengthens the leadership team ahead of these readouts.
At the time of this filing, TYRA was trading at $32.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $9.96 to $40.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.